D. E. Shaw & Co. Inc. Buys 165,220 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

D. E. Shaw & Co. Inc. lifted its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 287.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,608 shares of the biopharmaceutical company’s stock after purchasing an additional 165,220 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.45% of Puma Biotechnology worth $679,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. LPL Financial LLC raised its stake in shares of Puma Biotechnology by 23.6% during the 4th quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 5,080 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Puma Biotechnology by 42.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 5,726 shares during the period. Prudential Financial Inc. raised its stake in shares of Puma Biotechnology by 5.8% during the 4th quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 5,800 shares during the period. Wells Fargo & Company MN raised its stake in shares of Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 6,126 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Puma Biotechnology by 167.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 6,351 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Price Performance

Puma Biotechnology stock opened at $3.23 on Friday. Puma Biotechnology, Inc. has a 52 week low of $2.23 and a 52 week high of $4.13. The business has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $3.07. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a market cap of $160.31 million, a price-to-earnings ratio of 6.73 and a beta of 1.29.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $59.10 million during the quarter, compared to analysts’ expectations of $52.50 million. On average, research analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on PBYI. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.